We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Daiichi Sankyo Co Ltd | TG:D4S | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|
-0.66 | -2.02% | 32.00 | 291 | 18:18:02 |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
31.61 | 32.02 | 32.28 | 32.00 | 32.10 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
- |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
15:14:30 | 31 | 32.00 | EUR |
Date | Time | Source | Headline |
---|---|---|---|
27/5/2024 | 07:49 | ALNC | IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd |
25/4/2024 | 14:13 | ALNC | TOP NEWS: Daiichi forecasts further revenue growth after strong year |
08/4/2024 | 06:53 | ALNC | TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval |
03/4/2024 | 11:02 | ALNC | CORRECT: AstraZeneca, Daiichi make US progress with licence approvals |
02/4/2024 | 10:25 | ALNC | AstraZeneca and Daiichi make US progress with latest licence approvals |
05/3/2024 | 14:24 | ALNC | AstraZeneca's breast cancer treatment blocked for NHS use in England |
04/3/2024 | 09:31 | ALNC | AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment |
19/2/2024 | 15:39 | ALNC | UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax |
19/2/2024 | 08:36 | ALNC | TOP NEWS: AstraZeneca celebrates Tagrisso approval and new data |
31/1/2024 | 10:59 | ALNC | Daiichi Sankyo ups full-year guidance, as weak yen boosts third quarter |
Daiichi Sankyo (D4S) Share Charts1 Year Daiichi Sankyo Chart |
|
1 Month Daiichi Sankyo Chart |
Intraday Daiichi Sankyo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions